# US 2024/0252485 A1 · Pharmaceutical composition for nasal delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252485 A1
- Document ID: US20240252485A1
- Status: Published application
- Kind: A1
- Application number: 18/542,954
- Filed: 2023-12-18
- Published: 2024-08-01
- Earliest claimed: 2019-07-09
- Assignees: Orexo AB
- Applicants: Orexo AB
- Inventors: Jonas Sävmarker; Robert Rönn; Andreas Fischer
- Web page: https://patentgrep.com/patent/US20240252485A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0043: {Nose}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1682: {Processes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

## Claims

### Claim at position 1

-32. (canceled)

### Claim 33

A solid pharmaceutical composition in the form of a spray-dried powder comprising:
a pharmacologically-effective amount of nalmefene or a pharmaceutically-acceptable salt thereof; and
a pharmaceutically-acceptable carrier material comprising a combination of:
(i) a disaccharide selected from the group consisting of maltitol, trehalose, sucralose, sucrose, isomalt, maltose, and lactose; and
(ii) a dextrin;
wherein the composition is essentially free of water and is suitable for nasal delivery of nalmefene or the pharmaceutically-acceptable salt thereof, and the nalmefene or pharmaceutically-acceptable salt thereof is less than about 15% chemically degraded after storage for 3 months at 75% relative humidity and 40° C.

### Claim 34 (depends on 33)

The composition as claimed in claim 33, wherein the lowest measurable glass transition temperature of the composition is at least about 40° C. when measured at a relative humidity of about 35%.

### Claim 35 (depends on 33)

The composition as claimed in claim 33, wherein the particle size distribution of the spray-dried powder includes a Dv(10) that is above about 3 μm.

### Claim 36 (depends on 33)

The composition as claimed in claim 33, wherein the disaccharide comprises lactose and/or trehalose.

### Claim 37 (depends on 33)

The composition as claimed in claim 33, which further comprises an alkyl saccharide.

### Claim 38 (depends on 37)

The composition as claimed in claim 37, wherein the alkyl saccharide comprises a sucrose ester.

### Claim 39 (depends on 38)

The composition as claimed in claim 38, wherein the sucrose ester comprises sucrose monolaurate.

### Claim 40 (depends on 33)

The composition as claimed in claim 33, wherein the dextrin comprises a cyclodextrin or a maltodextrin.

### Claim 41 (depends on 33)

The composition as claimed in claim 33, wherein the carrier material comprises α-D-lactose monohydrate as the disaccharide and one or more of 2-hydroxypropyl-β-cyclodextrin and/or maltodextrin 12DE as the dextrin.

### Claim 42 (depends on 33)

The composition as claimed in claim 33, wherein the dextrin comprises a maltodextrin.

### Claim 43 (depends on 42)

The composition as claimed in claim 42, wherein the carrier material comprises α-D-lactose as the disaccharide, and a maltodextrin.

### Claim 44 (depends on 33)

The composition as claimed in claim 33, wherein the disaccharide is present in an amount of between about 10% and about 30% by weight based on the total weight of the composition.

### Claim 45 (depends on 33)

The composition as claimed in claim 33, wherein the ratio of disaccharide:dextrin is between about 10:1 and about 1:10 by weight based on the total weight of the composition.

### Claim 46 (depends on 33)

The composition as claimed in claim 33, wherein the powder has a particle size distribution that includes a volume-based mean diameter within the range of about 10 μm and about 100 μm.

### Claim 47 (depends on 33)

A process for the manufacturing of a pharmaceutical composition as defined in claim 33, wherein said process comprises the steps of:
(a) mixing together in a volatile solvent, nalmefene, or a pharmaceutically-acceptable salt thereof, and pharmaceutically-acceptable carrier materials; and
(b) spray-drying the mixture from step (a) to form the pharmaceutical composition comprising spray-dried particles.

### Claim 48 (depends on 47)

A composition obtainable by the process as defined in claim 47.

### Claim 49 (depends on 33)

A nasal applicator device suitable and/or adapted for delivery of the pharmaceutical composition as defined in claim 33 to the nose, which comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

### Claim 50 (depends on 49)

A process for the manufacturing of the applicator device as claimed in claim 49, the process comprising the steps of:
i) mixing together nalmefene or salt thereof and the pharmaceutically-acceptable carrier materials in a volatile solvent;
ii) spray-drying the mixture from step i) to form the pharmaceutical composition comprising spray-dried particles; and
iii) loading the pharmaceutical composition formed in step ii) into the reservoir within or adjunct or attached to said applicator device.

### Claim 51 (depends on 33)

A method of treating opioid overdose, which method comprises administering the composition as defined in claim 33 to a subject in need of such treatment.

### Claim 52 (depends on 51)

The method as claimed in claim 51, wherein the composition is administered to said subject by way of an applicator that comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

### Claim 53 (depends on 33)

The composition as claimed in claim 33, which comprises less than about 5% of water.

### Claim 54 (depends on 33)

The composition as claimed in claim 33, which comprises less than about 2% of water.

### Claim 55 (depends on 33)

The composition as claimed in claim 33, which comprises less than about 1% of water.

### Claim 56 (depends on 49)

The nasal applicator device as claimed in claim 49, which is packaged within a container that substantially prevents the ingress of atmospheric water under the storage conditions of 75% relative humidity and 40° C.

### Claim 57 (depends on 49)

The nasal applicator device as claimed in claim 49, which is packaged within a container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.

### Claim 58 (depends on 56)

A process for the manufacturing of an applicator device as claimed in claim 56, the process comprising:
i) mixing together nalmefene or salt thereof and the pharmaceutically-acceptable carrier materials in a volatile solvent;
ii) spray-drying the mixture from step i) to form the pharmaceutical composition comprising spray-dried particles;
iii) loading the pharmaceutical composition formed in step ii) into the reservoir within or adjunct or attached to said applicator device; and
iv) loading the applicator device from step iii) into the container that substantially prevents the ingress of atmospheric water.

### Claim 59 (depends on 57)

A process for the manufacturing of an applicator device as claimed in claim 57, the process comprising:
i) mixing together nalmefene or salt thereof and the pharmaceutically-acceptable carrier materials in a volatile solvent;
ii) spray-drying the mixture from step i) to form the pharmaceutical composition comprising spray-dried particles;
iii) loading the pharmaceutical composition formed in step ii) into the reservoir within or adjunct or attached to said applicator device; and
iv) loading the applicator device from step iii) into the container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.

### Claim 60 (depends on 33)

The composition as claimed in claim 33, wherein the nalmefene or pharmaceutically-acceptable salt thereof is less than about 10% chemically degraded after storage for 3 months at 75% relative humidity and 40° C.

### Claim 61 (depends on 60)

A nasal applicator device suitable and/or adapted for delivery of the composition as defined in claim 60 to the nose, which comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

### Claim 62 (depends on 61)

The nasal applicator device as claimed in claim 61, which is packaged within a container that substantially prevents the ingress of atmospheric water under the storage conditions of 75% relative humidity and 40° C.

### Claim 63 (depends on 61)

The nasal applicator device as claimed in claim 61, which is packaged within a container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.

### Claim 64 (depends on 33)

The composition as claimed in claim 33, wherein the nalmefene or pharmaceutically-acceptable salt thereof is less than about 5% chemically degraded after storage for 3 months at 75% relative humidity and 40° ° C.

### Claim 65 (depends on 64)

A nasal applicator device suitable and/or adapted for delivery of the composition as defined in claim 64 to the nose, which comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

### Claim 66 (depends on 65)

The nasal applicator device as claimed in claim 65, which is packaged within a container that substantially prevents the ingress of atmospheric water under the storage conditions of 75% relative humidity and 40° C.

### Claim 67 (depends on 65)

The nasal applicator device as claimed in claim 65, which is packaged within a container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.
